Express Scripts: HCV Formulary Could Change With Merck Combo's Approval
Executive Summary
Exclusive formulary position for AbbVie's Viekira Pak remains in place for 2016, but an approval of Merck's combo is expected to place further downward pressure on HCV drug prices, which could mean a broader formulary in 2017 and beyond.